Combined lowering of low grade systemic inflammation and insulin resistance in metabolic syndrome patients treated with Ginkgo biloba

• In a clinical pilot study with eleven metabolic syndrome patients, a simultaneous decrease in hs-CRP from 8.85 +/- 4.09 to 4.92 +/- 2.51 mg/L (-44.4%) (p < 0.0436) and HOMA-IR from 3.07 +/- 0.63 to 2.60 +/- 0.51 mU/L x mg/dL (-15.3%) (p < 0.0120) as well as a beneficial change of arteriosclerotic, inflammatory and oxidative stress biomarkers were detected after 2-month treatment with Ginkgo biloba. Furthermore, both IL-6 (-12.9%, p < 0.0407) and nanoplaque formation (-14.3%, p < 0.0077) were additionally reduced. According to a large clinical trial elucidating the importance of insulin resistance and low-grade systemic inflammation for cardiovascular disease and overall mortality risk, these data might indicate a CVD/total mortality risk reduction.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Nyckelord

Metabolic syndrome patients

High-sensitivity C-reactive protein (hs-CRP)

Homeostasis model assessment of insulin resistance (HOMA-IR)

CVD/total mortality risk

Ginkgo biloba

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)